FLAME 30
176 Reports in Pharmaceuticals
Active Pharmaceutical Ingredients: Global Markets to 2022
The global active pharmaceutical ingredient (API) market should reach $154.7 billion by 2022 from $114.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.2% for the period 2017-2022.
Neuroprotective Agents: Therapeutic Applications and Global Marke...
The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.
Antiulcerant Drugs: Global Markets to 2022
The global antiulcerant drugs market will grow from $33.0 billion in 2017 to $37.4 billion by 2022 with a compound annual growth rate (CAGR) of 2.5% for the period of 2017-2022.
Clinical Nutrition: Global Markets to 2022
The global clinical nutrition market should reach $60.8 billion by 2022 from $48.2 billion in 2017 at a compound annual growth rate (CAGR) of 4.8% for the period 2017-2022.
The Global Influenza Market
The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.
Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global...
The global market for circulating tumor cell technology will grow from nearly $4.6 billion in 2017 to around $10.3 billion by 2022 with a compound annual growth rate (CAGR) of 17.6% for the period of 2017-2022.
Excipients in Pharmaceuticals: Global Markets to 2022
The global market for pharmaceutical excipients will grow from nearly $6.8 billion in 2017 to $8.7 billion by 2022 with a compound annual growth rate (CAGR) of 4.9% for the period of 2017-2022.
Drugs for Urinary Incontinence and Overactive Bladder: Global Mar...
The global drugs for urinary incontinence and overactive bladder market should reach $4.2 billion by 2022 from $3.6 billion in 2017 at a compound annual growth rate (CAGR) of 2.9%, from 2017 to 2022.
Muscle Relaxants: Global Markets to 2022
The global muscle relaxants market totaled $18.4 billion in 2017 and is estimated to reach $24.4 billion by 2022, growing at a compound annual growth rate (CAGR) of 5.8% for the period of 2017-2022.
Anti-Epileptic Drugs: Global Markets to 2022
The global anti-epileptic drugs market totaled $8.4 billion in 2017 and is estimated to reach $9.5 billion by 2022, growing at a compound annual growth rate (CAGR) of 2.7% for the period of 2017-2022.
Drugs for Infertility: Global Markets to 2022
The global market for drugs for infertility should reach $4.2 billion by 2022 from $3.4 billion in 2017 at a compound annual growth rate (CAGR) of 4.3%, from 2017 to 2022.
Global Markets for Vaccine Technologies
The global market for vaccine technologies reached $35.7 billion in 2017 and should reach nearly $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 5.5% for the period of 2017-2022.
Cardiovascular Drugs: Global Markets to 2022
The global cardiovascular drugs market should reach $149.4 billion by 2022 from $141.1 billion in 2017 at a compound annual growth rate (CAGR) of 1.2%, from 2017 to 2022.
Small Molecule Therapies for Rheumatoid Arthritis: Global Markets...
The global small molecule therapies for rheumatoid arthritis market totaled $1.7 billion in 2017 and is estimated to reach $2.3 billion by 2022, growing at a compound annual growth rate (CAGR) of 6.6% for the period of 2017-2022.
Global Markets for Contract Pharmaceutical Manufacturing, Researc...
The global market for pharmaceutical contract manufacturing, contract research and contract packaging will grow from $136.4 billion in 2017 to $197.0 billion by 2022 with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.
Anti-Parkinson's Drugs: Global Markets to 2022
The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1% from 2017 to 2022.
Global Markets for Infectious Disease Treatments
The global market for infectious disease treatments totaled $64.8 billion in 2017. The market should total $99 billion by 2022, growing at a compound annual growth rate (CAGR) of 8.9% from 2017 to 2022.
Global Cancer Therapeutics Market: Emphasis on Recurrent and Meta...
The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
Medication Adherence: Systems, Technologies and Global Markets
The global market for medication adherence reached $1.7 billion in 2016 and should reach nearly $4.0 billion by 2021 at a compound annual growth rate (CAGR) of 18.0% from 2016 through 2021.
Substance Abuse and Addiction Treatment, Global Markets to 2021
The global substance abuse and addiction treatment market reached $3.1 billion in 2016 and should reach nearly $4.4 billion in 2021, at a compound annual growth rate (CAGR) of 7.0%.
Antibody Drug Conjugates: Technologies and Global Markets
The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021.
The Chinese Market for Cancer Intervention
The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022.
Global Markets for Allergy Diagnostics and Treatments
The global allergy diagnostic and treatment market reached nearly $35.3 billion in 2015. This market is expected to increase from nearly $40.0 billion in 2016 to $52.7 billion in 2021 at a compound annual growth rate (CAGR) of 5.9% for 2016-2021.
Global Markets for Neglected Tropical Disease Treatments
The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.
Drug Testing: Technologies and Global Markets
The global drug of abuse (DOA) testing market reached nearly $3.0 billion in 2016. This market is estimated to grow at a compound annual growth rate (CAGR) of 4.5% to reach nearly $3.9 billion by 2022 from $3.1 billion in 2017.
Choose your License
6 Upcoming Reports in Pharmaceuticals
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Report Includes
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights of the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile.
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
